Coral Drugs
Coral Drugs, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various regions. Founded in 1993, the company has established itself as a trusted manufacturer and supplier of high-quality pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished formulations. With a commitment to innovation and quality, Coral Drugs stands out for its state-of-the-art manufacturing facilities and adherence to stringent regulatory standards. The company has achieved significant milestones, including certifications from major global regulatory bodies, which underscore its market position. Coral Drugs is dedicated to enhancing healthcare through its diverse product portfolio, which caters to a wide range of therapeutic areas. Its focus on research and development further solidifies its reputation as a leader in the pharmaceutical sector.
DitchCarbon Score
How does Coral Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Coral Drugs's score of 0 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Coral Drugs's reported carbon emissions
Coral Drugs, headquartered in India, currently does not have publicly available carbon emissions data for the most recent year. As a result, specific figures regarding their carbon footprint, including Scope 1, 2, or 3 emissions, are not provided. In the absence of emissions data, it is important to note that Coral Drugs has not outlined any specific reduction targets or climate commitments. This lack of information suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly focuses on sustainability and reducing carbon emissions, Coral Drugs may benefit from establishing clear climate commitments and reduction initiatives to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Coral Drugs is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
